Clinical Trial Update: Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 [Phase 1]

View source ↗

Summary

Phase 1a/1b dose-escalation study of ARQ-234 in adults with atopic dermatitis and eczema is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• ARQ-234

Snippet

Sponsor: Arcutis Biotherapeutics, Inc. | Conditions: Atopic Dermatitis (AD), Eczema | Phase 1 | Status: RECRUITING